A Study to Assess the Effect of Shukra Shodhana dasemani Tablet in Patients with Acne.

A CLINICAL STUDY TO EVALUATE THE EFFECTIVENESS OF SHUKRA SHODHANA DASEMANI TABLET IN THE MANAGEMENT OF YAUVANPIDIKA W.S.R TO ACNE VULGARIS OPEN LABEL SINGLE ARM STUDY. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/102461

Enrollment

Registered

2026-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Gender: Male & Female Age: 16 to 25 years. Patient fulfilling the diagnostic criteria of yauvanpidika (acne vulgaris)

Exclusion criteria

Exclusion criteria: Side effects/ Hypersensitivity to any other drug will be excluded. Pidika due to any systemic diseases like Prameha, Masurika, were also excluded from the present study. Local applications containing Steroids and Narcotics are excluded Acne conglobata, Acne nodular, Herpes, and Nodular cystic acne are excluded. Cancer, AIDS, Psoriasis, TB, and other disorders that leads to fatal conditions for patients. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
To evaluate the change from baseline in the severity of pain (Vedana), burning sensation (Daha), inflammation (Paka), and discharge (Strava) in patients with Yauvanpidika after completion of the treatment period.Timepoint: 14 days	—

Secondary

Measure	Time frame
To evaluate the change from baseline in the number and size of acne lesions (pidika) after completion of the treatment period. To assess improvement in overall skin appearance and complexion following treatment. To evaluate overall clinical improvement in patients with Yauvanpidika based on patient-reported outcomes. To assess the safety and tolerability of Shukra Shodhana Dashemani Tablet during the study period.Timepoint: 14 days	—

Measure

Time frame

To evaluate the change from baseline in the number and size of acne lesions (pidika) after completion of the treatment period. To assess improvement in overall skin appearance and complexion following treatment. To evaluate overall clinical improvement in patients with Yauvanpidika based on patient-reported outcomes. To assess the safety and tolerability of Shukra Shodhana Dashemani Tablet during the study period.Timepoint: 14 days

—

Countries

India

Contacts

Public ContactDr Hiralben Ramjibhai Thakor

Shree Swaminarayan Ayurvedic College

pravinkharadi321@gmail.com9978136650

Outcome results